Source: MedPage Today
WASHINGTON — The FDA has approved the first influenza vaccine administered through a novel intradermal microinjection.
The Fluzone Intradermal vaccine is injected through an ultra-fine, 0.6 inch needle that is 90% shorter than most intramuscular flu vaccine needles, according to a statement from manufacturer Sanofi Pasteur. The vaccine works by generating an immune response from dendritic cells in the skin, according to the statement.
The Fluzone Intradermal vaccine is indicated for adult patients (age 18 to 64) for the subtype A and type B influenza virus, and consists of a 0.5 mL or 0.1 mL, prefilled dosage with 15 mcg and 9 mcg of hemagglutinin, respectively, per strain of influenza.
Read More: FDA OKs First Microinjection Flu Vaccine